• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis.钙通道阻滞剂单药治疗血压反应的种族差异:一项荟萃分析。
Am J Hypertens. 2009 Aug;22(8):911-7. doi: 10.1038/ajh.2009.100. Epub 2009 Jun 4.
2
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.肾素抑制剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD007066. doi: 10.1002/14651858.CD007066.pub3.
3
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
4
Multifaceted behavioral interventions to improve topical glaucoma therapy adherence in adults.多方面行为干预以提高成人局部青光眼治疗的依从性。
Cochrane Database Syst Rev. 2025 Jun 11;6(6):CD015788. doi: 10.1002/14651858.CD015788.pub2.
5
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.
6
Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker.依普利酮与三氯噻嗪对血压控制不佳的高血压患者的家庭血压降低效果:EXCITE-HT随机对照试验按基础钙通道阻滞剂与血管紧张素受体阻滞剂进行的预定义亚组分析
Hypertens Res. 2025 Feb;48(2):506-518. doi: 10.1038/s41440-024-01887-1. Epub 2024 Oct 12.
7
Oral beta-blockers for mild to moderate hypertension during pregnancy.孕期轻至中度高血压的口服β受体阻滞剂治疗
Cochrane Database Syst Rev. 2000;2003(4):CD002863. doi: 10.1002/14651858.CD002863.
8
A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.对固定低剂量培哚普利 - 吲达帕胺联合用药作为高血压一线治疗的疗效和安全性进行的系统评价与荟萃分析。
Clin Ther. 2004 Feb;26(2):257-70. doi: 10.1016/s0149-2918(04)90024-0.
9
Eplerenone for hypertension.依普利酮用于治疗高血压。
Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD008996. doi: 10.1002/14651858.CD008996.pub2.
10
Pharmacotherapy for hypertension in adults aged 18 to 59 years.18至59岁成年人高血压的药物治疗
Cochrane Database Syst Rev. 2017 Aug 16;8(8):CD008276. doi: 10.1002/14651858.CD008276.pub2.

引用本文的文献

1
Comparative Effectiveness of Calcium-Channel Blockers, Angiotensin-Converting Enzyme/Angiotensin Receptor Blockers and Diuretics on Cardiovascular Events Likelihood in Hypertensive African-American and Non-Hispanic Caucasians: A Retrospective Study Across HCA Healthcare.钙通道阻滞剂、血管紧张素转换酶/血管紧张素受体阻滞剂和利尿剂对非裔美国高血压患者及非西班牙裔白人心血管事件发生可能性的比较疗效:一项横跨HCA医疗集团的回顾性研究
Clin Cardiol. 2025 Jan;48(1):e70075. doi: 10.1002/clc.70075.
2
The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations.钙通道阻滞剂在高血压管理中的角色演变:药理学及临床考量
Curr Issues Mol Biol. 2024 Jun 22;46(7):6315-6327. doi: 10.3390/cimb46070377.
3
Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention.不同血统心血管疾病的遗传异质性:对发病机制和治疗干预的启示
Camb Prism Precis Med. 2023 Jan 10;1:e8. doi: 10.1017/pcm.2022.13. eCollection 2023.
4
Antihypertensive Medication Use and Its Effects on Blood Pressure and Haemodynamics in a Tri-ethnic Population Cohort: Southall and Brent Revisited (SABRE).三族裔人群队列中抗高血压药物的使用及其对血压和血流动力学的影响:再探索撒尔和布伦特(SABRE)
Front Cardiovasc Med. 2022 Jan 14;8:795267. doi: 10.3389/fcvm.2021.795267. eCollection 2021.
5
Association of West African ancestry and blood pressure control among African Americans taking antihypertensive medication in the Jackson Heart Study.西非人后裔与美国非洲裔降压药物治疗人群中的血压控制关联:杰克逊心脏研究。
J Clin Hypertens (Greenwich). 2020 Feb;22(2):157-166. doi: 10.1111/jch.13824. Epub 2020 Feb 12.
6
Lercanidipine in the Management of Hypertension: An Update.乐卡地平在高血压治疗中的应用:最新进展
J Pharmacol Pharmacother. 2017 Oct-Dec;8(4):155-165. doi: 10.4103/jpp.JPP_34_17.
7
Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling.初级医疗中的药物遗传学:个性化医学的前景与种族特征分析的现实。
Cult Med Psychiatry. 2013 Mar;37(1):226-35. doi: 10.1007/s11013-012-9303-x.
8
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study.按种族划分的 2 期高血压患者缬沙坦/氢氯噻嗪和氨氯地平/氢氯噻嗪联合治疗的 24 小时动态血压反应:EVALUATE 研究。
J Clin Hypertens (Greenwich). 2010 Nov;12(11):833-40. doi: 10.1111/j.1751-7176.2010.00372.x. Epub 2010 Sep 24.

本文引用的文献

1
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.心血管药物反应中的种族差异:药物遗传学的潜在作用。
Circulation. 2008 Sep 23;118(13):1383-93. doi: 10.1161/CIRCULATIONAHA.107.704023.
2
From black and white to shades of gray: race and renin-angiotensin system blockade.从黑白到灰度:种族与肾素-血管紧张素系统阻断
J Am Coll Cardiol. 2008 May 13;51(19):1872-3. doi: 10.1016/j.jacc.2008.01.039.
3
Differences in hypertension between blacks and whites: an overview.黑人和白人在高血压方面的差异:综述。
Cardiovasc J Afr. 2007 Jul-Aug;18(4):241-7.
4
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2007年动脉高血压管理指南:欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)动脉高血压管理特别工作组制定。
Eur Heart J. 2007 Jun;28(12):1462-536. doi: 10.1093/eurheartj/ehm236. Epub 2007 Jun 11.
5
BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.用于黑人患者心力衰竭治疗的BiDil:美国食品药品监督管理局批准的影响
Ann Intern Med. 2007 Jan 2;146(1):52-6. doi: 10.7326/0003-4819-146-1-200701020-00009.
6
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.BiDil(硝酸异山梨酯和肼屈嗪):两种旧药的新型固定剂量复方制剂,用于治疗黑人患者的心力衰竭。
Cardiol Rev. 2007 Jan-Feb;15(1):46-53. doi: 10.1097/01.crd.0000250840.15645.fb.
7
Management of hypertension in ethnic minorities.少数民族高血压的管理
Heart. 2005 Aug;91(8):1105-9. doi: 10.1136/hrt.2004.044560.
8
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.使用氯噻酮、氨氯地平和赖诺普利治疗的高血压黑人和非黑人患者的治疗结果。
JAMA. 2005 Apr 6;293(13):1595-608. doi: 10.1001/jama.293.13.1595.
9
Systematic review: antihypertensive drug therapy in black patients.系统评价:黑人患者的抗高血压药物治疗
Ann Intern Med. 2004 Oct 19;141(8):614-27. doi: 10.7326/0003-4819-141-8-200410190-00009.
10
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.高血压管理指南:英国高血压学会第四届工作组报告,2004年 - BHS IV
J Hum Hypertens. 2004 Mar;18(3):139-85. doi: 10.1038/sj.jhh.1001683.

钙通道阻滞剂单药治疗血压反应的种族差异:一项荟萃分析。

Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis.

作者信息

Nguyen Thu T, Kaufman Jay S, Whitsel Eric A, Cooper Richard S

机构信息

Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

出版信息

Am J Hypertens. 2009 Aug;22(8):911-7. doi: 10.1038/ajh.2009.100. Epub 2009 Jun 4.

DOI:10.1038/ajh.2009.100
PMID:19498341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6414055/
Abstract

BACKGROUND

A systematic literature review was conducted to determine whether US blacks and whites have differential blood pressure (BP) response to calcium channel blocker (CCB) monotherapy.

METHODS

Six published studies made up the final cohort of eligible articles. Multiple treatment groups within some studies led to a total of eight sets of estimates for BP reduction with a total of 6,851 white or nonblack participants and 3,371 black participants.

RESULTS

The pooled difference in systolic blood pressure (SBP) change between blacks and whites was -2.7 mm Hg (95% confidence interval (CI): -4.0, -1.3) with blacks having greater response. The difference in diastolic blood pressure (DBP) between blacks and whites was -0.4 mm Hg (95% CI: -1.0, 0.3) with blacks having greater response. Using a dichotomous outcome measure, whites were found to be just as likely as blacks to attain the DBP goal of <90 mm Hg or a 10 mm Hg or greater change (relative risk: 1.00 95% CI: 0.91, 1.11). In addition, examination of the continuous distribution of BP responses of whites and blacks showed over 90% overlap in treatment response.

CONCLUSION

Assessment of differential response to CCB monotherapy by race in published data depends on choice of outcome metric. Nonetheless, the results of this systematic review indicate that BP response is qualitatively similar in US blacks and whites, suggesting that patient race is not likely to offer any clinical utility for decisions about the likely effect of this antihypertensive therapy.

摘要

背景

进行了一项系统的文献综述,以确定美国黑人和白人对钙通道阻滞剂(CCB)单一疗法的血压(BP)反应是否存在差异。

方法

六项已发表的研究构成了符合条件文章的最终队列。一些研究中的多个治疗组导致总共八组血压降低的估计值,共有6851名白人或非黑人参与者和3371名黑人参与者。

结果

黑人和白人收缩压(SBP)变化的合并差异为-2.7 mmHg(95%置信区间(CI):-4.0,-1.3),黑人的反应更大。黑人和白人舒张压(DBP)的差异为-0.4 mmHg(95%CI:-1.0,0.3),黑人的反应更大。使用二分结局指标,发现白人达到DBP目标<90 mmHg或变化10 mmHg或更大的可能性与黑人相同(相对风险:1.00,95%CI:0.91,1.11)。此外,对白人和黑人血压反应的连续分布进行检查发现,治疗反应的重叠率超过90%。

结论

在已发表的数据中,按种族评估对CCB单一疗法的差异反应取决于结局指标的选择。尽管如此,这项系统综述的结果表明,美国黑人和白人的血压反应在质量上相似,这表明患者种族对于决定这种抗高血压疗法的可能效果不太可能具有任何临床实用性。